Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.

Methicillin-resistant Staphylococcus aureus (MRSA) with decreased susceptibility to glycopeptides can be categorized as first, heteroresistant to vancomycin (hVISA); second, with intermediate susceptibility to vancomycin (VISA); and third, fully resistant to vancomycin (VRSA). Whereas the hVISA and VISA isolates are characterized by increased cell wall thickness, activated cell wall synthesis and reduced autolysis, VRSA harbor the vanA gene cluster resulting in a remodeled peptidoglycan. Nonsusceptibility to daptomycin has been associated with changes in the structure and function of the cell envelope and surface charge. Linezolid resistance in MRSA is often associated with mutations in the 23S rRNA, although resistance mediated by an acquired gene (cfr encoding a 23S rRNA methyltransferase) has now been documented in several continents and in outbreak settings.

[1]  M. Moore,et al.  Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.

[2]  P. Courvalin,et al.  VanA-Type Vancomycin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[3]  A. Bayer,et al.  Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. , 2009, The Journal of infectious diseases.

[4]  Jaime Moreno,et al.  Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase , 2008, Journal of Clinical Microbiology.

[5]  Xilin Zhao,et al.  Mutant selection window hypothesis updated. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Shahsavan,et al.  Emergence of High-Level Vancomycin-Resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran , 2008, Medical Principles and Practice.

[7]  H. Kalbacher,et al.  The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion , 2009, PLoS pathogens.

[8]  G. Sakoulas,et al.  Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. , 2009, The Lancet. Infectious diseases.

[9]  G. Eliopoulos,et al.  Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin , 2006, Antimicrobial Agents and Chemotherapy.

[10]  H. Boucher,et al.  Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Gracia Morales,et al.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[13]  J. Patel,et al.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  H. Chambers,et al.  Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods , 2003, Antimicrobial Agents and Chemotherapy.

[15]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[16]  G. Eliopoulos,et al.  Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus. , 2007, The Journal of antimicrobial chemotherapy.

[17]  J. Gatell,et al.  Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis , 2008, Antimicrobial Agents and Chemotherapy.

[18]  K. Hiramatsu.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. , 2001, The Lancet. Infectious diseases.

[19]  S. Schwarz,et al.  Identification of a Plasmid-Borne Chloramphenicol-Florfenicol Resistance Gene inStaphylococcus sciuri , 2000, Antimicrobial Agents and Chemotherapy.

[20]  Paul D. R. Johnson,et al.  Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.

[21]  L. Cui,et al.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[22]  P. Appelbaum.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). , 2007, International journal of antimicrobial agents.

[23]  Ronald N. Jones.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  A. MacGowan,et al.  Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates , 2006, Antimicrobial Agents and Chemotherapy.

[25]  Ronald N. Jones,et al.  The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Hancock,et al.  Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. , 2004, Chemistry & biology.

[27]  J. Alós,et al.  Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. , 2008, The Journal of antimicrobial chemotherapy.

[28]  B. Bozdoğan,et al.  Oxazolidinones: activity, mode of action, and mechanism of resistance. , 2004, International journal of antimicrobial agents.

[29]  J. Poehlsgaard,et al.  The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics , 2006, Antimicrobial Agents and Chemotherapy.

[30]  J. Miro,et al.  Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[31]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[32]  I. Chopra,et al.  Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. , 2008, The Journal of antimicrobial chemotherapy.

[33]  A. Tomasz,et al.  Overexpression of Genes of the Cell Wall Stimulon in Clinical Isolates of Staphylococcus aureus Exhibiting Vancomycin-Intermediate- S. aureus-Type Resistance to Vancomycin , 2006, Journal of bacteriology.

[34]  J. Schrenzel,et al.  Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding , 2007, Antimicrobial Agents and Chemotherapy.

[35]  J. Shetty,et al.  Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus , 2003, Science.

[36]  G. Bierbaum,et al.  Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. , 2007, International journal of medical microbiology : IJMM.

[37]  J. Timsit,et al.  Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  A. Kumar,et al.  Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus , 2008 .

[39]  J. Patel,et al.  Vancomycin-Resistant Staphylococcus aureus, Michigan, USA, 2007 , 2009, Emerging infectious diseases.

[40]  A. MacGowan,et al.  A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides , 2006, Journal of Clinical Microbiology.

[41]  Ronald N. Jones,et al.  Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). , 2008, Diagnostic microbiology and infectious disease.

[42]  P. Ward,et al.  Prospective Comparison of the Clinical Impacts of Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Susceptible MRSA , 2009, Antimicrobial Agents and Chemotherapy.

[43]  J. Patel,et al.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  Ronald N. Jones,et al.  First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States , 2008, Antimicrobial Agents and Chemotherapy.

[45]  J. A. Andrews,et al.  Linezolid resistance in clinical isolates of Staphylococcus aureus. , 2003, The Journal of antimicrobial chemotherapy.

[46]  J. Quinn,et al.  Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  G. Eliopoulos,et al.  Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. , 2006, The Journal of antimicrobial chemotherapy.

[48]  A. Wong-Beringer,et al.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.

[49]  J. Patel,et al.  Vancomycin-Resistant Staphylococcus aureus Isolates Associated with Inc18-Like vanA Plasmids in Michigan , 2007, Antimicrobial Agents and Chemotherapy.

[50]  P. Ward,et al.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Anil Kumar Singh,et al.  Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). , 2008, Journal of medical microbiology.

[52]  Jerome J. Schentag,et al.  Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2007, Antimicrobial Agents and Chemotherapy.

[53]  J. Sarria,et al.  Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. , 2005, The American journal of the medical sciences.

[54]  T. Wichelhaus,et al.  Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances , 2008, Antimicrobial Agents and Chemotherapy.

[55]  J. Quinn,et al.  Acquisition of a natural resistance gene renders a clinical strain of methicillin‐resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid , 2007, Molecular microbiology.